{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:15:13Z","timestamp":1794071713026,"version":"4.8.0"},"reference-count":38,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2017,5,29]]},"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>\u200bBackground<\/jats:title>\n                    <jats:p>\n                      The clinical severity of disease in neurofibromatosis type 2 (NF2) is variable. Patients affected with a constitutional truncating\n                      <jats:italic>NF2<\/jats:italic>\n                      mutation have severe disease, while missense mutations or mosaic mutations present with a milder attenuated phenotype. Genotype-derived natural history data are important to inform discussions on prognosis and management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have assessed NF2 clinical phenotype in 142 patients in relation to the UK NF2 Genetic Severity Score to validate its use as a clinical and research tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Genetic Severity Score showed significant correlations across 10 measures, including mean age at diagnosis, proportion of patients with bilateral vestibular schwannomas, presence of intracranial meningioma, spinal meningioma and spinal schwannoma, NF2 eye features, hearing grade, age at first radiotherapy, age at first surgery and age starting bevacizumab. In addition there was moderate but significant correlation with age at loss of useful hearing, and weak but significant correlations for mean age at death, quality of life, last optimum Speech Discrimination Score and total number of major interventions. Patients with severe disease presented at a younger age had a higher disease burden and greater requirement of intervention than patients with mild and moderate disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study validates the UK NF2 Genetic Severity Score to stratify patients with NF2 for both clinical use and natural history studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jmedgenet-2017-104519","type":"journal-article","created":{"date-parts":[[2017,8,28]],"date-time":"2017-08-28T20:40:24Z","timestamp":1503952824000},"page":"657-664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":148,"title":["Genetic Severity Score predicts clinical phenotype in NF2"],"prefix":"10.1136","volume":"54","author":[{"given":"Dorothy","family":"Halliday","sequence":"first","affiliation":[{"name":"Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK"},{"name":"Oxford NF2 Unit, Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Emmanouil","sequence":"additional","affiliation":[{"name":"Oxford NF2 Unit, Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Pretorius","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"MacKeith","sequence":"additional","affiliation":[{"name":"Department of ENT, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Painter","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tomkins","sequence":"additional","affiliation":[{"name":"Department of Neurology, Derriford Hospital, Plymouth, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8482-5784","authenticated-orcid":false,"given":"D Gareth","family":"Evans","sequence":"additional","affiliation":[{"name":"Genomic Medicine, Division of Evolution and Genomic Sciences, University of Manchester, Manchester, Greater Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Parry","sequence":"additional","affiliation":[{"name":"Oxford NF2 Unit, Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Nuffield Department of Neurosciences, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,28]]},"reference":[{"key":"2025101800243991000_54.10.657.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33139"},{"key":"2025101800243991000_54.10.657.2","doi-asserted-by":"publisher","DOI":"10.1038\/363515a0"},{"key":"2025101800243991000_54.10.657.3","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.34.11.934"},{"key":"2025101800243991000_54.10.657.4","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/7.13.2051"},{"key":"2025101800243991000_54.10.657.5","doi-asserted-by":"publisher","DOI":"10.1086\/302004"},{"key":"2025101800243991000_54.10.657.6","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.29.12.841"},{"key":"2025101800243991000_54.10.657.7","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q J Med"},{"key":"2025101800243991000_54.10.657.8","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103290"},{"key":"2025101800243991000_54.10.657.9","doi-asserted-by":"publisher","DOI":"10.1086\/342716"},{"key":"2025101800243991000_54.10.657.10","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050255"},{"key":"2025101800243991000_54.10.657.11","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.35.6.450"},{"key":"2025101800243991000_54.10.657.12","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2002.96.2.0217"},{"key":"2025101800243991000_54.10.657.13","first-page":"529","article-title":"Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities","volume":"59","author":"Parry","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2025101800243991000_54.10.657.14","first-page":"331","article-title":"Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease","volume":"59","author":"Ruttledge","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2025101800243991000_54.10.657.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01315.x"},{"key":"2025101800243991000_54.10.657.16","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.10181"},{"key":"2025101800243991000_54.10.657.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9091(98)80003-X"},{"key":"2025101800243991000_54.10.657.18","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2002.96.2.0223"},{"key":"2025101800243991000_54.10.657.19","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2003.99.3.0480"},{"key":"2025101800243991000_54.10.657.20","doi-asserted-by":"publisher","DOI":"10.1086\/422700"},{"key":"2025101800243991000_54.10.657.21","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2010.085241"},{"key":"2025101800243991000_54.10.657.22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/cge.12007","article-title":"Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity","volume":"83","author":"Evans","year":"2013","journal-title":"Clin Genet"},{"key":"2025101800243991000_54.10.657.23","first-page":"69","article-title":"A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals","volume":"55","author":"Bourn","year":"1994","journal-title":"Am J Hum Genet"},{"key":"2025101800243991000_54.10.657.24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19980518)77:3<228::AID-AJMG8>3.0.CO;2-L"},{"key":"2025101800243991000_54.10.657.25","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.029504"},{"key":"2025101800243991000_54.10.657.26","doi-asserted-by":"crossref","unstructured":"Lloyd SK , Evans DG . Neurofibromatosis type 2 service delivery in England. Neurochirurgie 2016. Advance online publication http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0028377015002799 (accessed 29 Jul 2016).doi:10.1016\/j.neuchi.2015.10.006","DOI":"10.1016\/j.neuchi.2015.10.006"},{"key":"2025101800243991000_54.10.657.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7303-1"},{"key":"2025101800243991000_54.10.657.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.5.1132"},{"key":"2025101800243991000_54.10.657.29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/gcc.20733","article-title":"Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes","volume":"49","author":"Abo-Dalo","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"2025101800243991000_54.10.657.30","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0b013e3182a1a8b4"},{"key":"2025101800243991000_54.10.657.31","first-page":"104","article-title":"The NFTI-QOL: a Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2. Journal of neurological surgery Part B","volume":"73","author":"Hornigold","year":"2012","journal-title":"Skull base"},{"key":"2025101800243991000_54.10.657.32","unstructured":"NHS Health Research Authority. Defining Research: Research Ethics Service guidance to help you decide if your project requires review by a Research Ethics Committee,http:\/\/wwwhranhsuk\/documents\/2016\/06\/defining-researchpdf London:Department of Health 2016."},{"key":"2025101800243991000_54.10.657.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2011.01816.x"},{"key":"2025101800243991000_54.10.657.34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2014-102973","article-title":"Bilateral vestibular schwannomas in older patients: NF2 or chance?","volume":"52","author":"Evans","year":"2015","journal-title":"J Med Genet"},{"key":"2025101800243991000_54.10.657.35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","article-title":"Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis","volume":"88","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"2025101800243991000_54.10.657.36","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos218"},{"key":"2025101800243991000_54.10.657.37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20088"},{"key":"2025101800243991000_54.10.657.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070972"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2017-104519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:24:52Z","timestamp":1760772292000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2017-104519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,28]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/jmedgenet-2017-104519"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2017-104519","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,28]]}}}